Results 91 to 100 of about 4,877,471 (249)

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

CD133 marks a stem cell population that drives human primary myelofibrosis

Haematologica, 2015
Primary myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, extramedullary hematopoiesis, and transformation to acute myeloid leukemia.
Ioanna Triviai, Thomas Stübig, Birte Niebuhr, Kais Hussein, Asterios Tsiftsoglou, Boris Fehse, Carol Stocking, Nicolaus Kröger   +7 more
doaj   +1 more source

Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms? [PDF]

, 2021
Jean‐Antoine Ribeil
openalex   +1 more source

Primary myelofibrosis with increased haemoglobin concentration at presentation

British Journal of Haematology, EarlyView.
Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Annalisa De Silvestri, Robert Peter Gale, Vittorio Rosti   +8 more
wiley   +1 more source

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis

Haematologica, 2009
CD146+ bone marrow stromal cells have been recently recognized as clonogenic osteoprogenitors able to organize a complete hematopoietic microenvironment.
Claudio Tripodo, Andrea Di Bernardo, Maria Paola Ternullo, Carla Guarnotta, Rossana Porcasi, Sabrina Ingrao, Umberto Gianelli, Emanuela Boveri, Emilio Iannitto, Giovanni Franco, Ada Maria Florena   +10 more
doaj   +1 more source

Translocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis. [PDF]

, 1999
peer reviewedTranslocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly.
Albert Thiry, Berger, Bitter, Christian Herens, Fleischman, Fonatsch, Francoise Tassin, Georges Fillet, Griggs, Horsman, Jean-Philippe Hermanne, Kwong, Kwong, Levaltier, Lucien Koulischer, Marie France Fassotte, Mauricette Jamar, Mecucci, Nicole Schaaf-Lafontaine, Prigogina, Secker-Walker, Whang-Peng, Yunis   +22 more
core   +1 more source

Improvement in Primary Autoimmune Myelofibrosis Following a Short Course of Steroids and Intravenous Immunoglobulins [PDF]

, 2022
Swathi Prakash, Sara Alhariri, Mariam Hassan, Priya K Patel, Javier Corral   +4 more
openalex   +1 more source

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients

Leukemia, 2018
Anemia is one of the major risk factors for survival in primary myelofibrosis (PMF). Current prognostic models in PMF, including the International Prognostic Scoring System (IPSS) [1], dynamic IPSS (DIPSS) [2] and DIPSS-plus [3], all list hemoglobin ...
M. Nicolosi, M. Mudireddy, T. Lasho, C. Hanson, R. Ketterling, N. Gangat, A. Pardanani, A. Tefferi   +7 more
semanticscholar   +1 more source

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

British Journal of Haematology, EarlyView.
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown, Rebekah Bennett, Clare Crean, Andrew Hindley, Julie McGimpsey, Nicholas Cunningham, Aaron Niblock, Suzanne McPherson, Kathryn Boyd, Allister Foy, Ciaren Graham, Graeme Greenfield, Mary Frances McMullin, Mark A. Catherwood   +13 more
wiley   +1 more source

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis

Journal of Hematology & Oncology, 2017
We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia ...
Bing Li, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Zhen Song, Peihong Zhang, Jie Bai, Lei Zhang, Yue Zhang, Jinqin Liu, Gang Huang, Zhijian Xiao   +11 more
doaj   +1 more source